Northwest Biotherapeutics (NWBO) Cash & Equivalents (2010 - 2026)

Northwest Biotherapeutics' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $1.8 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 35.73% year-over-year to $1.8 million; the TTM figure through Mar 2026 stood at $1.8 million (down 35.73% YoY), while the FY2025 annual figure was $3.0 million, up 39.77% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $1.8 million, down from $3.0 million in the prior quarter.
• The five-year high for Cash & Equivalents was $9.4 million in Q3 2022, with the low at $1.4 million in Q2 2023.
• The 5-year median for Cash & Equivalents is $3.0 million (2025), against an average of $4.2 million.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents surged 145.7% in 2022, then sank 70.52% in 2023.
• Northwest Biotherapeutics' Cash & Equivalents stood at $7.0 million in 2022, then tumbled by 69.48% to $2.1 million in 2023, then increased by 2.3% to $2.2 million in 2024, then jumped by 39.77% to $3.0 million in 2025, then plunged by 41.25% to $1.8 million in 2026.
• Business Quant data shows NWBO's Cash & Equivalents at $1.8 million in Q1 2026, $3.0 million in Q4 2025, and $4.6 million in Q3 2025.